Response to Letter Regarding Article, “Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke with Proven Occlusion”
We thank Dr Behrouz1 for their letter. We are in agreement that further trials of tenecteplase in stroke are needed, but are cautious about making conclusions based on comparisons of noncontemporaneous controls. The Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2) study2 will examine the effect of tenecteplase versus control among patients with minor stroke and proven intracranial occlusion. We think that it critical to add the element of noninvasive vascular imaging to studies of thrombolytic agents. We are looking forward to beginning the study in the second quarter of 2015.
Shelagh B. Coutts, MD, FRCPC
Michael D. Hill, MD, FRCPC
Departments of Clinical Neurosciences and Radiology
Hotchkiss Brain Institute
University of Calgary
Calgary, Alberta, Canada
Study drug for the TEMPO-1 trial was provided by Hoffman-La Roche Canada.
Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.
- © 2015 American Heart Association, Inc.
- Behrouz R, Mutgi SA, Silver B
- 2.↵Clinical Trials.gov. A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2). Clinical Trials.gov Web site. https://clinicaltrials.gov/ct2/show/NCT02398656?term=Coutts&rank=1. Accessed March 26, 2015.